Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2003

Open Access 01-12-2003 | Short communication

Regulation of COX-2 transcription in a colon cancer cell line by Pontin52/TIP49a

Authors: Mary L Carlson, Ellen T Wilson, Stephen M Prescott

Published in: Molecular Cancer | Issue 1/2003

Login to get access

Abstract

Cyclooxygenase-2 (COX-2) is expressed early in colon carcinogenesis and is known to play a crucial role in the progress of the disease. Here we show that the regulation of the expression of this enzyme in a colon cancer cell line, and in patients, is associated with overexpression of the Wnt pathway-associated proteins, Pontin52/TIP49a and LEF-1. Recently shown to be essential for transformation via the c-Myc pathway, Pontin52/TIP49a promotes COX-2 expression in tissue culture and is overexpressed in colon cancer tissue, co-localizing with COX-2 expression in transformed tissue, relative to paired normal tissue.
Appendix
Available only for authorised users
Literature
1.
Prescott SM, Fitzpatrick FA: Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta. 2000, 1470: M69-M78.PubMed
2.
Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, Murray FE: The relationship between cyclooxygenase-2 expression and colorectal cancer. Jama. 1999, 282: 1254-1257.CrossRefPubMed
3.
Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, White RL, Prescott SM: Prostaglandin H synthase-2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA. 1996, 93: 4816-4820.PubMedCentralCrossRefPubMed
4.
Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ: Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 1999, 274: 10911-10915.CrossRefPubMed
5.
6.
Polakis P: Wnt signaling and cancer. Genes Dev. 2000, 14: 1837-1851.PubMed
7.
Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ, Brown AM: Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells. Cancer Res. 1999, 59: 1572-1577.PubMed
8.
Bauer A, Huber O, Kemler R: Pontin52, an interaction partner of beta-catenin, binds to the TATA box binding protein. Proc Natl Acad Sci U S A. 1998, 95: 14787-14792.PubMedCentralCrossRefPubMed
9.
Kanemaki M, Makino Y, Yoshida T, Kishimoto T, Koga A, Yamamoto K, Yamamoto M, Moncollin V, Egly JM, Muramatsu M, Tamura T: Molecular cloning of a rat 49-kDa TBP-interacting protein (TIP49) that is highly homologous to the bacterial RuvB. Biochem Biophys Res Commun. 1997, 235: 64-68.CrossRefPubMed
10.
Wood MA, McMahon SB, Cole MD: An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. Mol Cell. 2000, 5: 321-330.CrossRefPubMed
11.
Henriksson M, Luscher B: Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res. 1996, 68: 109-182.CrossRefPubMed
12.
Sladek TL: E2F transcription factor action, regulation and possible role in human cancer. Cell Prolif. 1997, 30: 97-105.CrossRefPubMed
13.
Stone J, de Lange T, Ramsay G, Jakobovits E, Bishop JM, Varmus H, Lee W: Definition of regions in human c-myc that are involved in transformation and nuclear localization. Mol Cell Biol. 1987, 7: 1697-1709.PubMedCentralCrossRefPubMed
14.
Freytag SO, Dang CV, Lee WM: Definition of the activities and properties of c-myc required to inhibit cell differentiation. Cell Growth Differ. 1990, 1: 339-343.PubMed
15.
16.
Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC: Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992, 69: 119-128.CrossRefPubMed
17.
Li LH, Nerlov C, Prendergast G, MacGregor D, Ziff EB: c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. Embo J. 1994, 13: 4070-4079.PubMedCentralPubMed
18.
Kanemaki M, Kurokawa Y, Matsu-ura T, Makino Y, Masani A, Okazaki K, Morishita T, Tamura TA: TIP49b, a new RuvB-like DNA helicase, is included in a complex together with another RuvB-like DNA helicase, TIP49a. J Biol Chem. 1999, 274: 22437-22444.CrossRefPubMed
19.
Kurokawa Y, Kanemaki M, Makino Y, Tamura TA: A notable example of an evolutionary conserved gene: studies on a putative DNA helicase TIP49. DNA Seq. 1999, 10: 37-42.PubMed
20.
Ikura T, Ogryzko VV, Grigoriev M, Groisman R, Wang J, Horikoshi M, Scully R, Qin J, Nakatani Y: Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell. 2000, 102: 463-473.CrossRefPubMed
21.
Shen X, Mizuguchi G, Hamiche A, Wu C: A chromatin remodelling complex involved in transcription and DNA processing. Nature. 2000, 406: 541-544.CrossRefPubMed
22.
Cho SG, Bhoumik A, Broday L, Ivanov V, Rosenstein B, Ronai Z: TIP49b, a regulator of activating transcription factor 2 response to stress and DNA damage. Mol Cell Biol. 2001, 21: 8398-8413.PubMedCentralCrossRefPubMed
23.
Jonsson ZO, Dhar SK, Narlikar GJ, Auty R, Wagle N, Pellman D, Pratt RE, Kingston R, Dutta A: Rvb1p and Rvb2p are essential components of a chromatin remodeling complex that regulates transcription of over 5% of yeast genes. J Biol Chem. 2001, 276: 16279-16288.CrossRefPubMed
24.
Saurin AJ, Shao Z, Erdjument-Bromage H, Tempst P, Kingston RE: A Drosophila Polycomb group complex includes Zeste and dTAFII proteins. Nature. 2001, 412: 655-660.CrossRefPubMed
25.
Makino Y, Kanemaki M, Kurokawa Y, Koji T, Tamura T: A rat RuvB-like protein, TIP49a, is a germ cell-enriched novel DNA helicase. J Biol Chem. 1999, 274: 15329-15335.CrossRefPubMed
26.
Bauer A, Chauvet S, Huber O, Usseglio F, Rothbacher U, Aragnol D, Kemler R, Pradel J: Pontin52 and reptin52 function as antagonistic regulators of beta-catenin signalling activity. Embo J. 2000, 19: 6121-6130.PubMedCentralCrossRefPubMed
27.
Rottbauer W, Saurin AJ, Lickert H, Shen X, Burns CG, Wo ZG, Kemler R, Kingston R, Wu C, Fishman M: Reptin and pontin antagonistically regulate heart growth in zebrafish embryos. Cell. 2002, 111: 661-672.CrossRefPubMed
28.
Dugan KA, Wood MA, Cole MD: TIP49, but not TRRAP, modulates c-Myc and E2F1 dependent apoptosis. Oncogene. 2002, 21: 5835-5843.CrossRefPubMed
29.
Brantjes H, Barker N, van Es J, Clevers H: TCF: Lady Justice casting the final verdict on the outcome of Wnt signalling. Biol Chem. 2002, 383: 255-261.CrossRefPubMed
30.
Barker N, Morin PJ, Clevers H: The Yin-Yang of TCF/beta-catenin signaling. Adv Cancer Res. 2000, 77: 1-24.CrossRefPubMed
31.
Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H: Constitutive transcriptional activation by a b-catenin-Tcf complex in APC-/- colon carcinoma. Science. 1997, 275: 1784-1787.CrossRefPubMed
32.
Miller JR, Hocking AM, Brown JD, Moon RT: Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene. 1999, 18: 7860-7872.CrossRefPubMed
33.
Haertel-Wiesmann M, Liang Y, Fantl WJ, Williams LT: Regulation of cyclooxygenase-2 and periostin by Wnt-3 in mouse mammary epithelial cells. J Biol Chem. 2000, 275: 32046-32051.CrossRefPubMed
34.
Cao Y, Murphy KJ, McIntyre TM, Zimmerman GA, Prescott SM: Expression of fatty acid-CaA ligase 4 during development and in brain. FEBS Lett. 2000, 467: 263-267.CrossRefPubMed
Metadata
Title
Regulation of COX-2 transcription in a colon cancer cell line by Pontin52/TIP49a
Authors
Mary L Carlson
Ellen T Wilson
Stephen M Prescott
Publication date
01-12-2003
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2003
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-2-42

Other articles of this Issue 1/2003

Molecular Cancer 1/2003 Go to the issue

Review

Pathways for aberrant angiogenesis in pancreatic cancer

Review

The Biology of the Ets1 Proto-Oncogene

Review

Molecular responses to hypoxia in tumor cells

Review

Genetic alterations in pancreatic carcinoma

Review

Genetic abnormalities in pancreatic cancer

Research

SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits